No licensed hantavirus vaccine is approved for broad use in the United States or Europe as of mid-2026, with candidates largely confined to preclinical animal models or early Phase 1/2 trials. DNA and mRNA platforms targeting strains like Andes virus or Hantaan virus have shown neutralizing antibodies in rodents and nonhuman primates, yet none have advanced to Phase 3 efficacy testing. Recent 2026 outbreaks, including Andes virus cases on a cruise ship, prompted renewed research interest but have not accelerated regulatory timelines or secured large-scale funding comparable to Operation Warp Speed. Trader consensus at 94.5% on “No” reflects these standard vaccine development constraints and limited commercial incentives for this rare pathogen, though unexpected emergency authorizations or rapid trial success could still shift outcomes before year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% 機率
$129,738 交易量
$129,738 交易量
2026-12-30
6% 機率
$129,738 交易量
$129,738 交易量
2026-12-30
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine is approved for broad use in the United States or Europe as of mid-2026, with candidates largely confined to preclinical animal models or early Phase 1/2 trials. DNA and mRNA platforms targeting strains like Andes virus or Hantaan virus have shown neutralizing antibodies in rodents and nonhuman primates, yet none have advanced to Phase 3 efficacy testing. Recent 2026 outbreaks, including Andes virus cases on a cruise ship, prompted renewed research interest but have not accelerated regulatory timelines or secured large-scale funding comparable to Operation Warp Speed. Trader consensus at 94.5% on “No” reflects these standard vaccine development constraints and limited commercial incentives for this rare pathogen, though unexpected emergency authorizations or rapid trial success could still shift outcomes before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市場開放時間： May 4, 2026, 10:39 AM ET
交易量
$129,738結束日期
2026-12-31市場開放時間
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine is approved for broad use in the United States or Europe as of mid-2026, with candidates largely confined to preclinical animal models or early Phase 1/2 trials. DNA and mRNA platforms targeting strains like Andes virus or Hantaan virus have shown neutralizing antibodies in rodents and nonhuman primates, yet none have advanced to Phase 3 efficacy testing. Recent 2026 outbreaks, including Andes virus cases on a cruise ship, prompted renewed research interest but have not accelerated regulatory timelines or secured large-scale funding comparable to Operation Warp Speed. Trader consensus at 94.5% on “No” reflects these standard vaccine development constraints and limited commercial incentives for this rare pathogen, though unexpected emergency authorizations or rapid trial success could still shift outcomes before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$129,738結束日期
2026-12-31市場開放時間
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No licensed hantavirus vaccine is approved for broad use in the United States or Europe as of mid-2026, with candidates largely confined to preclinical animal models or early Phase 1/2 trials. DNA and mRNA platforms targeting strains like Andes virus or Hantaan virus have shown neutralizing antibodies in rodents and nonhuman primates, yet none have advanced to Phase 3 efficacy testing. Recent 2026 outbreaks, including Andes virus cases on a cruise ship, prompted renewed research interest but have not accelerated regulatory timelines or secured large-scale funding comparable to Operation Warp Speed. Trader consensus at 94.5% on “No” reflects these standard vaccine development constraints and limited commercial incentives for this rare pathogen, though unexpected emergency authorizations or rapid trial success could still shift outcomes before year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions